Most US companies comply with PMS commitments, says FDA
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has adopted new measures, and is considering further changes to its policies, to improve the timeline and quality of postmarketing studies that drug makers are required to undertake1.